Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIFICO plus bismuth quadruple therapy for refractory Helicobacter pylori infection
ChiCTR1900023008Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- May 2019
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of bifidobacterium longum/lactobacillus acidophilus/enterococcus faecalis, esomeprazole, bismuth subcitrate, amoxicillin and furazolidone in Helicobacter pylori infection and Refractory Helicobacter pylori infection (2 arms), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Effect of BIFICO combined with quadruple therapy on gastrointestinal microecology. Started May 2019; status: recruiting.
02
Drugs
bifidobacterium longum/lactobacillus acidophilus/enterococcus faecalisesomeprazolebismuth subcitrateamoxicillinfurazolidone
03
Conditions
Helicobacter pylori infectionRefractory Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR1900023008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023008.